Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasm Metastasis 1Delirium 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cisplatin 7Carboplatin 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4Capecitabine 4Calcium Dobesilate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Haloperidol × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡